HAIFA, Israel, Oct. 1, 2009 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) today announced, that on September 23, 2009, it filed its Annual Report on Form 10-K with the SEC, which included an audit report by the company's independent registered public accounting firm containing a going concern qualification. The company makes this announcement in compliance with NASDAQ Marketplace Rule 5250(b)(2). The company's auditors had previously issued going concern opinions for its fiscal years 2008, 2007 and 2006, in addition to several prior years.
About Pluristem
Pluristem is a clinical stage biotechnology company with proprietary technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem's patented and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases.
See our product animation on YouTube: Animation, the content of which is not part of this press release.
For more information visit our website at www.pluristem.com, the content of which is not part of this press release.